 Michael Wilson
Concepts (260)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pathology | 7 | 2018 | 21 | 3.220 |
Why?
| | Clinical Laboratory Techniques | 9 | 2019 | 97 | 2.900 |
Why?
| | Global Health | 9 | 2025 | 404 | 2.420 |
Why?
| | Pathology, Clinical | 5 | 2018 | 29 | 1.660 |
Why?
| | Diagnostic Techniques and Procedures | 3 | 2023 | 19 | 1.550 |
Why?
| | Clinical Laboratory Services | 3 | 2018 | 5 | 1.140 |
Why?
| | Laboratories | 6 | 2022 | 110 | 0.990 |
Why?
| | Pathologists | 2 | 2024 | 19 | 0.950 |
Why?
| | Autopsy | 3 | 2014 | 95 | 0.850 |
Why?
| | Malaria | 3 | 2014 | 73 | 0.800 |
Why?
| | Molecular Diagnostic Techniques | 3 | 2015 | 104 | 0.790 |
Why?
| | Education, Medical | 4 | 2015 | 273 | 0.750 |
Why?
| | Health Services Accessibility | 4 | 2025 | 1101 | 0.740 |
Why?
| | Quality of Health Care | 3 | 2018 | 693 | 0.670 |
Why?
| | Antitubercular Agents | 2 | 2013 | 216 | 0.620 |
Why?
| | Internship and Residency | 3 | 2015 | 1265 | 0.600 |
Why?
| | Communicable Diseases | 3 | 2008 | 166 | 0.590 |
Why?
| | Health Services Needs and Demand | 2 | 2018 | 279 | 0.580 |
Why?
| | Tuberculosis | 2 | 2013 | 292 | 0.570 |
Why?
| | Mycobacterium tuberculosis | 2 | 2013 | 339 | 0.560 |
Why?
| | Early Diagnosis | 1 | 2019 | 251 | 0.540 |
Why?
| | Reimbursement Mechanisms | 2 | 2015 | 79 | 0.520 |
Why?
| | Education, Medical, Continuing | 2 | 2018 | 134 | 0.520 |
Why?
| | Pathology, Surgical | 1 | 2017 | 6 | 0.500 |
Why?
| | Humans | 61 | 2025 | 145491 | 0.500 |
Why?
| | Developing Countries | 5 | 2021 | 317 | 0.490 |
Why?
| | Health Equity | 1 | 2019 | 133 | 0.480 |
Why?
| | Parasitemia | 2 | 2013 | 15 | 0.480 |
Why?
| | Calciphylaxis | 1 | 2015 | 2 | 0.460 |
Why?
| | Search Engine | 1 | 2015 | 12 | 0.460 |
Why?
| | Microbiology | 1 | 2015 | 24 | 0.450 |
Why?
| | Diagnostic Tests, Routine | 2 | 2017 | 107 | 0.450 |
Why?
| | Evidence-Based Medicine | 1 | 2019 | 738 | 0.440 |
Why?
| | Health Services Misuse | 1 | 2015 | 35 | 0.440 |
Why?
| | Malaria, Vivax | 1 | 2014 | 4 | 0.430 |
Why?
| | Pathology, Molecular | 1 | 2014 | 25 | 0.420 |
Why?
| | Antimalarials | 1 | 2014 | 35 | 0.420 |
Why?
| | Malaria, Falciparum | 1 | 2014 | 33 | 0.420 |
Why?
| | Efficiency | 1 | 2015 | 104 | 0.410 |
Why?
| | Medical Laboratory Personnel | 1 | 2014 | 6 | 0.410 |
Why?
| | Drug Resistance, Bacterial | 3 | 2013 | 206 | 0.400 |
Why?
| | Artificial Intelligence | 1 | 2018 | 383 | 0.400 |
Why?
| | Leiomyoma | 1 | 2014 | 59 | 0.390 |
Why?
| | Plasmodium | 1 | 2013 | 13 | 0.390 |
Why?
| | Reagent Kits, Diagnostic | 1 | 2013 | 34 | 0.390 |
Why?
| | Uterine Neoplasms | 1 | 2014 | 96 | 0.380 |
Why?
| | Diagnosis | 2 | 2025 | 16 | 0.380 |
Why?
| | Neoplasms | 3 | 2018 | 2897 | 0.370 |
Why?
| | Students, Medical | 2 | 2014 | 375 | 0.360 |
Why?
| | Population Surveillance | 2 | 2018 | 485 | 0.350 |
Why?
| | Cooperative Behavior | 1 | 2014 | 464 | 0.340 |
Why?
| | Bacteriological Techniques | 1 | 2011 | 68 | 0.330 |
Why?
| | Otitis Media | 2 | 2024 | 181 | 0.330 |
Why?
| | United States Public Health Service | 1 | 2010 | 9 | 0.320 |
Why?
| | Genomics | 2 | 2019 | 834 | 0.320 |
Why?
| | Immunoassay | 2 | 2011 | 108 | 0.310 |
Why?
| | Physicians | 2 | 2015 | 952 | 0.290 |
Why?
| | Communication | 1 | 2015 | 975 | 0.280 |
Why?
| | Community Health Services | 1 | 2010 | 231 | 0.270 |
Why?
| | Influenza A Virus, H1N1 Subtype | 1 | 2009 | 158 | 0.270 |
Why?
| | Referral and Consultation | 1 | 2014 | 862 | 0.270 |
Why?
| | Health Personnel | 1 | 2014 | 750 | 0.260 |
Why?
| | Soft Tissue Infections | 1 | 2008 | 40 | 0.260 |
Why?
| | Bone Diseases | 1 | 2008 | 61 | 0.260 |
Why?
| | Joint Diseases | 1 | 2008 | 62 | 0.250 |
Why?
| | Haemophilus influenzae | 2 | 2024 | 67 | 0.250 |
Why?
| | Microbiological Techniques | 2 | 2008 | 34 | 0.250 |
Why?
| | Latent Tuberculosis | 2 | 2018 | 71 | 0.240 |
Why?
| | Polymerase Chain Reaction | 1 | 2009 | 1049 | 0.240 |
Why?
| | Biological Evolution | 3 | 2025 | 488 | 0.240 |
Why?
| | Skin Diseases | 1 | 2008 | 152 | 0.240 |
Why?
| | Forensic Pathology | 1 | 2005 | 9 | 0.230 |
Why?
| | Government Agencies | 1 | 2005 | 14 | 0.230 |
Why?
| | Health Facility Closure | 1 | 2005 | 8 | 0.230 |
Why?
| | Vocalization, Animal | 1 | 2025 | 28 | 0.220 |
Why?
| | Academies and Institutes | 1 | 2005 | 60 | 0.220 |
Why?
| | Pan troglodytes | 1 | 2025 | 63 | 0.220 |
Why?
| | Urinary Tract Infections | 2 | 2004 | 210 | 0.210 |
Why?
| | Conjunctivitis, Bacterial | 1 | 2024 | 12 | 0.210 |
Why?
| | Music | 1 | 2025 | 48 | 0.210 |
Why?
| | Urine | 1 | 2004 | 64 | 0.200 |
Why?
| | Amoxicillin | 1 | 2024 | 35 | 0.200 |
Why?
| | Military Medicine | 1 | 2005 | 148 | 0.200 |
Why?
| | Influenza, Human | 1 | 2009 | 623 | 0.200 |
Why?
| | Armed Conflicts | 1 | 2023 | 15 | 0.190 |
Why?
| | Meta-Analysis as Topic | 2 | 2013 | 171 | 0.180 |
Why?
| | Sensitivity and Specificity | 3 | 2013 | 2002 | 0.180 |
Why?
| | Rifampin | 2 | 2013 | 82 | 0.180 |
Why?
| | Health Policy | 1 | 2025 | 399 | 0.170 |
Why?
| | Isoniazid | 2 | 2013 | 71 | 0.170 |
Why?
| | Microbial Sensitivity Tests | 3 | 2013 | 378 | 0.170 |
Why?
| | World Health Organization | 3 | 2020 | 104 | 0.170 |
Why?
| | Interferon-gamma Release Tests | 2 | 2018 | 32 | 0.170 |
Why?
| | Logical Observation Identifiers Names and Codes | 1 | 2020 | 1 | 0.170 |
Why?
| | Clinical Laboratory Information Systems | 1 | 2020 | 4 | 0.170 |
Why?
| | Women's Health | 2 | 2013 | 308 | 0.160 |
Why?
| | Urban Population | 3 | 2018 | 494 | 0.160 |
Why?
| | Levamisole | 2 | 2011 | 21 | 0.160 |
Why?
| | Gonorrhea | 1 | 2021 | 63 | 0.160 |
Why?
| | Chlamydia Infections | 1 | 2021 | 79 | 0.150 |
Why?
| | Cost of Illness | 1 | 2022 | 324 | 0.150 |
Why?
| | Point-of-Care Systems | 2 | 2019 | 188 | 0.150 |
Why?
| | Clinical Coding | 1 | 2019 | 26 | 0.150 |
Why?
| | Papio | 1 | 2019 | 69 | 0.150 |
Why?
| | Anti-Bacterial Agents | 3 | 2024 | 1953 | 0.150 |
Why?
| | Cocaine | 2 | 2011 | 161 | 0.140 |
Why?
| | Diagnostic Imaging | 1 | 2021 | 342 | 0.140 |
Why?
| | Africa | 3 | 2015 | 119 | 0.140 |
Why?
| | Behavior, Animal | 2 | 2019 | 526 | 0.140 |
Why?
| | Socioeconomic Factors | 2 | 2021 | 1327 | 0.140 |
Why?
| | Insurance, Health, Reimbursement | 1 | 2019 | 97 | 0.140 |
Why?
| | Africa South of the Sahara | 1 | 2018 | 54 | 0.140 |
Why?
| | Urban Health Services | 1 | 2018 | 71 | 0.140 |
Why?
| | Health Education | 2 | 2018 | 345 | 0.140 |
Why?
| | Infant | 5 | 2024 | 10064 | 0.130 |
Why?
| | Leukemoid Reaction | 1 | 2016 | 3 | 0.130 |
Why?
| | Social Behavior | 1 | 2019 | 288 | 0.130 |
Why?
| | GATA1 Transcription Factor | 1 | 2016 | 18 | 0.130 |
Why?
| | Acute Disease | 3 | 2024 | 1040 | 0.120 |
Why?
| | Sexual and Gender Minorities | 1 | 2021 | 260 | 0.120 |
Why?
| | Diseases in Twins | 1 | 2016 | 115 | 0.120 |
Why?
| | Public Health | 2 | 2018 | 573 | 0.120 |
Why?
| | Mass Screening | 2 | 2018 | 1358 | 0.120 |
Why?
| | Point Mutation | 1 | 2016 | 242 | 0.120 |
Why?
| | Clinical Audit | 1 | 2015 | 14 | 0.110 |
Why?
| | Cost Control | 1 | 2015 | 37 | 0.110 |
Why?
| | Utilization Review | 1 | 2015 | 39 | 0.110 |
Why?
| | Human Activities | 1 | 2015 | 21 | 0.110 |
Why?
| | Enterocolitis, Pseudomembranous | 1 | 2015 | 29 | 0.110 |
Why?
| | Benchmarking | 1 | 2016 | 190 | 0.110 |
Why?
| | Female | 14 | 2025 | 78763 | 0.110 |
Why?
| | Immunologic Factors | 1 | 2016 | 260 | 0.100 |
Why?
| | Medication Therapy Management | 1 | 2015 | 72 | 0.100 |
Why?
| | Hominidae | 1 | 2015 | 87 | 0.100 |
Why?
| | Drug Contamination | 2 | 2011 | 53 | 0.100 |
Why?
| | Plasmodium vivax | 1 | 2014 | 6 | 0.100 |
Why?
| | Hospitals | 1 | 2019 | 732 | 0.100 |
Why?
| | Agranulocytosis | 2 | 2011 | 30 | 0.100 |
Why?
| | Child, Preschool | 5 | 2024 | 11837 | 0.100 |
Why?
| | Neoplasm Staging | 1 | 2018 | 1468 | 0.100 |
Why?
| | Parasite Load | 1 | 2013 | 10 | 0.100 |
Why?
| | Antigens, Protozoan | 1 | 2013 | 32 | 0.100 |
Why?
| | Conservation of Natural Resources | 1 | 2015 | 133 | 0.100 |
Why?
| | Infection Control | 1 | 2015 | 174 | 0.100 |
Why?
| | Parasitology | 1 | 2012 | 9 | 0.090 |
Why?
| | Adult | 10 | 2021 | 40707 | 0.090 |
Why?
| | AIDS-Related Opportunistic Infections | 1 | 2013 | 130 | 0.090 |
Why?
| | Anti-Infective Agents | 1 | 2015 | 244 | 0.090 |
Why?
| | Cross Infection | 1 | 2015 | 264 | 0.090 |
Why?
| | Time Factors | 2 | 2013 | 7171 | 0.090 |
Why?
| | HIV | 1 | 2013 | 252 | 0.090 |
Why?
| | Proteome | 1 | 2016 | 517 | 0.090 |
Why?
| | DNA, Bacterial | 1 | 2013 | 347 | 0.090 |
Why?
| | Coinfection | 1 | 2013 | 144 | 0.090 |
Why?
| | Child | 7 | 2024 | 22680 | 0.080 |
Why?
| | Dopamine Uptake Inhibitors | 1 | 2011 | 59 | 0.080 |
Why?
| | Reproducibility of Results | 2 | 2023 | 3424 | 0.080 |
Why?
| | Infant, Newborn | 3 | 2016 | 6437 | 0.080 |
Why?
| | Down Syndrome | 1 | 2016 | 525 | 0.080 |
Why?
| | Proteomics | 1 | 2016 | 1191 | 0.080 |
Why?
| | Cocaine-Related Disorders | 1 | 2011 | 133 | 0.080 |
Why?
| | Clinical Competence | 1 | 2018 | 1242 | 0.080 |
Why?
| | Adjuvants, Immunologic | 1 | 2011 | 246 | 0.070 |
Why?
| | Escherichia coli | 2 | 2004 | 857 | 0.070 |
Why?
| | Pregnancy | 3 | 2016 | 7197 | 0.070 |
Why?
| | Education, Medical, Graduate | 1 | 2014 | 564 | 0.070 |
Why?
| | United States | 4 | 2016 | 16115 | 0.070 |
Why?
| | Quality Control | 1 | 2008 | 164 | 0.070 |
Why?
| | Comorbidity | 1 | 2013 | 1659 | 0.070 |
Why?
| | Nucleic Acid Amplification Techniques | 1 | 2008 | 39 | 0.070 |
Why?
| | Histocytochemistry | 1 | 2008 | 78 | 0.070 |
Why?
| | Male | 12 | 2025 | 72817 | 0.070 |
Why?
| | Predictive Value of Tests | 1 | 2013 | 2129 | 0.070 |
Why?
| | Tuberculin Test | 2 | 2018 | 36 | 0.070 |
Why?
| | Primary Health Care | 1 | 2018 | 1734 | 0.060 |
Why?
| | Adolescent | 5 | 2021 | 22485 | 0.060 |
Why?
| | Young Adult | 3 | 2021 | 14192 | 0.060 |
Why?
| | Peripheral Vascular Diseases | 1 | 2008 | 107 | 0.060 |
Why?
| | Protective Clothing | 1 | 2006 | 15 | 0.060 |
Why?
| | Quality Improvement | 1 | 2015 | 1294 | 0.060 |
Why?
| | Museums | 1 | 2005 | 11 | 0.060 |
Why?
| | Periodicity | 1 | 2025 | 58 | 0.060 |
Why?
| | Biomarkers | 1 | 2016 | 4283 | 0.060 |
Why?
| | Haemophilus Infections | 1 | 2024 | 45 | 0.050 |
Why?
| | Amoxicillin-Potassium Clavulanate Combination | 1 | 2024 | 16 | 0.050 |
Why?
| | Bacterial Typing Techniques | 1 | 2004 | 44 | 0.050 |
Why?
| | Enterobacteriaceae | 1 | 2004 | 44 | 0.050 |
Why?
| | Case-Control Studies | 2 | 2024 | 3619 | 0.050 |
Why?
| | Species Specificity | 1 | 2025 | 573 | 0.050 |
Why?
| | beta-Lactamases | 1 | 2024 | 53 | 0.050 |
Why?
| | Anti-Infective Agents, Urinary | 1 | 2003 | 16 | 0.050 |
Why?
| | Bronchopneumonia | 1 | 2003 | 6 | 0.050 |
Why?
| | Trimethoprim, Sulfamethoxazole Drug Combination | 1 | 2003 | 43 | 0.050 |
Why?
| | Hospitals, Public | 1 | 2003 | 30 | 0.050 |
Why?
| | Nasopharynx | 1 | 2023 | 73 | 0.050 |
Why?
| | Multiplex Polymerase Chain Reaction | 1 | 2023 | 54 | 0.050 |
Why?
| | Mycobacterium Infections | 1 | 2003 | 61 | 0.050 |
Why?
| | Escherichia coli Infections | 1 | 2003 | 126 | 0.050 |
Why?
| | Chorioamnionitis | 1 | 2003 | 50 | 0.050 |
Why?
| | Ghana | 1 | 2022 | 43 | 0.050 |
Why?
| | Pneumonia, Pneumocystis | 1 | 2002 | 34 | 0.050 |
Why?
| | Colorado | 4 | 2018 | 4572 | 0.050 |
Why?
| | Mycoses | 1 | 2003 | 88 | 0.050 |
Why?
| | Granuloma | 1 | 2002 | 97 | 0.050 |
Why?
| | HIV Seropositivity | 1 | 2002 | 119 | 0.040 |
Why?
| | Streptococcus pneumoniae | 1 | 2023 | 180 | 0.040 |
Why?
| | Fetal Diseases | 1 | 2003 | 194 | 0.040 |
Why?
| | Neisseria gonorrhoeae | 1 | 2021 | 29 | 0.040 |
Why?
| | Bacterial Infections | 1 | 2003 | 247 | 0.040 |
Why?
| | Middle Aged | 4 | 2018 | 36176 | 0.040 |
Why?
| | Chlamydia trachomatis | 1 | 2021 | 49 | 0.040 |
Why?
| | Antiretroviral Therapy, Highly Active | 1 | 2002 | 279 | 0.040 |
Why?
| | Urban Health | 1 | 2021 | 96 | 0.040 |
Why?
| | Virus Diseases | 1 | 2003 | 218 | 0.040 |
Why?
| | Risk Factors | 3 | 2018 | 10874 | 0.040 |
Why?
| | Retrospective Studies | 4 | 2021 | 17269 | 0.040 |
Why?
| | Prevalence | 2 | 2021 | 2855 | 0.040 |
Why?
| | Phylogeography | 1 | 2019 | 55 | 0.040 |
Why?
| | Homosexuality, Male | 1 | 2021 | 232 | 0.040 |
Why?
| | Ecology | 1 | 2019 | 122 | 0.030 |
Why?
| | Telepathology | 1 | 2018 | 4 | 0.030 |
Why?
| | Emergency Service, Hospital | 1 | 2010 | 2379 | 0.030 |
Why?
| | Models, Animal | 1 | 2019 | 395 | 0.030 |
Why?
| | Morbidity | 1 | 2018 | 322 | 0.030 |
Why?
| | Pregnancy, Triplet | 1 | 2016 | 5 | 0.030 |
Why?
| | Enzyme-Linked Immunospot Assay | 1 | 2016 | 37 | 0.030 |
Why?
| | Bacteria | 1 | 2023 | 897 | 0.030 |
Why?
| | Animals | 4 | 2025 | 38141 | 0.030 |
Why?
| | Twins, Monozygotic | 1 | 2016 | 134 | 0.030 |
Why?
| | Lung Diseases | 1 | 2002 | 783 | 0.030 |
Why?
| | Drug Resistance, Microbial | 1 | 2015 | 71 | 0.030 |
Why?
| | Time | 1 | 2015 | 86 | 0.030 |
Why?
| | HIV Infections | 1 | 2010 | 3189 | 0.030 |
Why?
| | Asia | 1 | 2014 | 72 | 0.030 |
Why?
| | Emigrants and Immigrants | 1 | 2016 | 158 | 0.030 |
Why?
| | Safety Management | 1 | 2015 | 125 | 0.030 |
Why?
| | Program Development | 1 | 2015 | 369 | 0.020 |
Why?
| | Research | 1 | 2015 | 432 | 0.020 |
Why?
| | Vasculitis, Leukocytoclastic, Cutaneous | 1 | 2011 | 8 | 0.020 |
Why?
| | False Negative Reactions | 1 | 2011 | 61 | 0.020 |
Why?
| | Leukoencephalopathies | 1 | 2011 | 24 | 0.020 |
Why?
| | Gas Chromatography-Mass Spectrometry | 1 | 2011 | 127 | 0.020 |
Why?
| | Crack Cocaine | 1 | 2010 | 9 | 0.020 |
Why?
| | Hospitals, Urban | 1 | 2011 | 143 | 0.020 |
Why?
| | Program Evaluation | 1 | 2015 | 945 | 0.020 |
Why?
| | Leukopenia | 1 | 2010 | 33 | 0.020 |
Why?
| | Evolution, Molecular | 1 | 2014 | 518 | 0.020 |
Why?
| | Leukocyte Count | 1 | 2010 | 316 | 0.020 |
Why?
| | Neutropenia | 1 | 2010 | 155 | 0.020 |
Why?
| | Treatment Outcome | 1 | 2024 | 11831 | 0.020 |
Why?
| | Phylogeny | 1 | 2014 | 1028 | 0.020 |
Why?
| | Aging | 1 | 2019 | 1940 | 0.020 |
Why?
| | Informed Consent | 1 | 2010 | 197 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2018 | 5426 | 0.020 |
Why?
| | Bone Marrow | 1 | 2010 | 307 | 0.020 |
Why?
| | Cognition | 1 | 2015 | 1268 | 0.020 |
Why?
| | Patient Compliance | 1 | 2010 | 587 | 0.010 |
Why?
| | Molecular Epidemiology | 1 | 2003 | 73 | 0.010 |
Why?
| | Community-Acquired Infections | 1 | 2003 | 177 | 0.010 |
Why?
| | Prospective Studies | 1 | 2003 | 8039 | 0.010 |
Why?
|
|
Wilson's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|